Please describe your clinical practice. How many patients with ovarian cancer do you see on a yearly basis? What percent of ovarian cancers become platinum-resistant and how do you measure benefit when proceeding with treatment?

Could you please tell us more about the mechanisms of platinum resistance, and the treatment options patients with PROC have?

How successful have monoclonal antibodies such as bevacizumab, (which blocks blood-vessel formation by inhibiting vascular endothelial growth factor VEGF) been, in treating PROC?

Are drugs that target the cell cycle in platinum-resistant disease more encouraging, such as blocking the cell-cycle control protein ATR and/or Wee1 (adavosertib)?

How often is toxicity a major problem in patients who have already gone through many rounds of therapy, and how do you manage that?

Corcept reported a 33% reduction in risk of death for Relacorilant + nab-paclitaxel compared to women treated with nab-paclitaxel alone. Median OS was 13.9 months, compared to 12.2 months for women receiving nab-paclitaxel monotherapy. Could you please discuss these results, and what it means for you?

Can you touch briefly on the recently reported mirvetuximab soravtansine Phase 3 data from ImmunoGen?

Do you think Relacorilant has the potential to supplant or adjuvate other combination molecules in PROC? How likely are you to use it in the future, if approved?